{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:49Z","timestamp":1794047449826,"version":"4.8.0"},"reference-count":22,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>CALYPSO (clinicaltrials gov. Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron overload. Iron chelation therapy-naive and iron chelation therapy-pretreated patients aged 2 to &lt;18 years with transfusion- dependent anemias were enrolled. Patients were randomized 1:1 to deferasirox granules or DT for 48 weeks, stratified by age group and prior iron chelation therapy. In this study, the co-primary objectives are to evaluate compliance and change from baseline in serum ferritin after 24 weeks for both formulations in iron chelation therapy-naive patients. In total, 224 patients, mostly with \u03b2-thalassemia major (63.4%), were randomized to granules (N=112) or DT (N=112). Primary analysis was conducted when 96 iron chelation therapy-naive patients had completed 24 weeks of treatment\/discontinued early; least squares mean (LSM) compliance in the deferasirox granules and DT groups, was 86.8% and 84.3% (difference 2.6%; P=0.360) respectively, while least squares mean change from baseline in serum ferritin was +4.8 and -171.5 ng\/mL (difference: 176.4 ng\/mL; P=0.255). Slight differences were observed in the observer\/patient-reported outcome scores between the granule and dispersible-tablet groups and the overall scores indicate good adherence, satisfaction\/preference, fewer concerns and good palatability with both deferasirox formulations. Safety analyses (N=221) found that the most frequently observed adverse events (granules and DT) were increased urine protein\/creatinine ratio (&gt;0.5 mg\/mg; 24.5% and 34.2%), upper respiratory tract infection (28.2% and 29.7%), and pyrexia (26.4% and 23.4%). In iron chelation therapy-naive patients, mean compliance and change from baseline in serum ferritin with both deferasirox formulations were not significantly different. The safety profile was comparable between granule and DT formulations, and was consistent with the general safety profile of deferasirox.<\/jats:p>","DOI":"10.3324\/haematol.2023.283133","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T03:37:44Z","timestamp":1697686664000},"page":"1413-1425","source":"Crossref","is-referenced-by-count":5,"title":["Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study"],"prefix":"10.3324","volume":"109","author":[{"given":"Ali T.","family":"Taher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cecilia","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimlak","family":"Charoenkwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Aydinok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameera","family":"Govindaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Romen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vip","family":"Viprakasit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"60469","doi-asserted-by":"crossref","unstructured":"Fernandes JL, Fabron A, Verissimo M. Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica. 2009; 94(12):1776-1777.","DOI":"10.3324\/haematol.2009.013193"},{"key":"60470","doi-asserted-by":"crossref","unstructured":"Gordan R, Wongjaikam S, Gwathmey JK, Chattipakorn N, Chattipakorn SC, Xie LH. Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update. Heart Fail Rev. 2018; 23(5):801-816.","DOI":"10.1007\/s10741-018-9700-5"},{"key":"60471","doi-asserted-by":"crossref","unstructured":"Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med. 2015; 6:197-209.","DOI":"10.2147\/JBM.S72463"},{"key":"60472","doi-asserted-by":"crossref","unstructured":"Vichinsky E, Butensky E, Fung E. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol. 2005; 80(1):70-74.","DOI":"10.1002\/ajh.20402"},{"key":"60473","unstructured":"Novartis Pharma AG. Exjade\u00ae (deferasirox) [Prescribing information]. U.S. Food and Drug Administration. 2009."},{"key":"60474","doi-asserted-by":"crossref","unstructured":"Aydinok Y, Unal S, Oymak Y. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naive children with transfusional iron overload. Eur J Haematol. 2012; 88(5):431-438.","DOI":"10.1111\/j.1600-0609.2012.01769.x"},{"key":"60475","doi-asserted-by":"crossref","unstructured":"Vichinsky E, El-Beshlawy A, Al Zoebie A. Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: results from a 5-year observational study (ENTRUST). Pediatr Blood Cancer. 2017; 64(9):e26507.","DOI":"10.1002\/pbc.26507"},{"key":"60476","doi-asserted-by":"crossref","unstructured":"Osborne RH, De Abreu Lourenco R, Dalton A. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health. 2007; 10(6):451-456.","DOI":"10.1111\/j.1524-4733.2007.00200.x"},{"key":"60477","doi-asserted-by":"crossref","unstructured":"Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007; 25(4):329-342.","DOI":"10.2165\/00019053-200725040-00005"},{"key":"60478","doi-asserted-by":"crossref","unstructured":"Haghpanah S, Zarei T, Zahedi Z, Karimi M. Compliance and satisfaction with deferasirox (Exjade(R)) compared with deferoxamine in patients with transfusion-dependent betathalassemia. Hematology. 2014; 19(4):187-191.","DOI":"10.1179\/1607845413Y.0000000121"},{"key":"60479","doi-asserted-by":"crossref","unstructured":"Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol. 2008; 83(5):398-402.","DOI":"10.1002\/ajh.21119"},{"key":"60480","doi-asserted-by":"crossref","unstructured":"Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996; 95(1):26-36.","DOI":"10.1159\/000203853"},{"key":"60481","doi-asserted-by":"crossref","unstructured":"Delea TE, Edelsberg J, Sofrygin O. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007; 47(10):1919-1929.","DOI":"10.1111\/j.1537-2995.2007.01416.x"},{"key":"60482","doi-asserted-by":"crossref","unstructured":"Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000; 355(9220):2051-2052.","DOI":"10.1016\/S0140-6736(00)02357-6"},{"key":"60483","unstructured":"Novartis Pharmaceuticals Corporation. JADENU\u00ae (deferasirox) [Prescribing Information]. U.S. Food and Drug Administration. 2020."},{"key":"60484","doi-asserted-by":"crossref","unstructured":"Trachtenberg F, Vichinsky E, Haines D. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011; 86(5):433-436.","DOI":"10.1002\/ajh.21993"},{"key":"60485","doi-asserted-by":"crossref","unstructured":"Cappellini MD, Cohen A, Piga A. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006; 107(9):3455-3462.","DOI":"10.1182\/blood-2005-08-3430"},{"key":"60486","doi-asserted-by":"crossref","unstructured":"Taher A, El-Beshlawy A, Elalfy MS. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009; 82(6):458-465.","DOI":"10.1111\/j.1600-0609.2009.01228.x"},{"key":"60487","doi-asserted-by":"crossref","unstructured":"Higashino S, Yasu T, Momo K, Kuroda S. Effects of formulation changes for deferasirox from dispersible tablets to granules in patients with red blood cell transfusion-induced iron overload. Am J Ther. 2019; 26(6):e728-e730.","DOI":"10.1097\/MJT.0000000000000882"},{"key":"60488","doi-asserted-by":"crossref","unstructured":"Taher AT, Origa R, Perrotta S. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017; 92(5):420-428.","DOI":"10.1002\/ajh.24668"},{"key":"60489","doi-asserted-by":"crossref","unstructured":"Chuang GT, Tsai IJ, Tsau YK, Lu MY. Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use. Nephrology (Carlton). 2015; 20(12):931-935.","DOI":"10.1111\/nep.12523"},{"key":"60490","doi-asserted-by":"crossref","unstructured":"Yacobovich J, Stark P, Barzilai-Birenbaum S. Acquired proximal renal tubular dysfunction in beta-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol. 2010; 32(7):564-567.","DOI":"10.1097\/MPH.0b013e3181ec0c38"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283133\/76173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283133\/76935","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11305\/76173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:06Z","timestamp":1794045906000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283133","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,19]]}}}